1. Hornung WP, Kieserg A, Feldmann R, Buchkremer G. Psychoeducational training for schizophrenic
patients: background, procedure and empirical findings. Patient Educ Couns. 1996;29(3):257–68.
2. Gaebel W. Towards the improvement of compliance: the significance of psychoeducation and new
antipsychotic drugs. Int Clin Psychopharmacol. 1997;12(Suppl 1):S37–42.
3. Pekkala E, Merinder L. Psychoeducation for schizophrenia. Cochrane Database Syst Rev.
2002;(2):CD002831. https://doi.org/10.1002/14651858.CD002831
4. Xia J, Merinder LB, Belgamwar MR. Psychoeducation for schizophrenia. Cochrane Database Syst Rev.
2011;(6):CD002831. https://doi.org/10.1002/14651858.CD002831.pub2
5. Hellewell JS. Patients’ subjective experiences of antipsychotics: clinical relevance. CNS Drugs.
2002;16(7):457–71.
6. Karow A, Naber D. Subjective well-being and quality of life under atypical antipsychotic treatment.
Psychopharmacology (Berl). 2002;162(1):3–10.
7. Revicki DA. Cost effectiveness of the newer atypical antipsychotics: a review of the pharmacoeconomic
research evidence. Curr Opin Investig Drugs. 2001;2(1):110–7.
8. Bechdolf A, Knost B, Kuntermann C, Schiller S, Klosterkötter J, Hambrecht M, et al. A randomized
comparison of group cognitive-behavioural therapy and group psychoeducation in patients with
schizophrenia. Acta Psychiatr Scand. 2004;110(1):21–8.
9. Herz MI, Lamberti JS, Mintz J, Scott R, O’Dell SP, McCartan L, et al. A program for relapse prevention
in schizophrenia: a controlled study. Arch Gen Psychiatry. 2000;57(3):277–83.
10. Aguglia E, Pascolo-Fabrici E, Bertossi F, Bassi M. Psychoeducational intervention and prevention of
relapse among schizophrenic disorders in the Italian community psychiatric network. Clin Pract Epidemiol
Ment Health. 2007;3(7):1–12.
11. Holmes H, Ziemba J, Evans T, Williams CA. Nursing model of psychoeducation for the seriously
mentally ill patient. Issues Ment Health Nurs. 1994;15(1):85–104.
12. Hornung WP, Klingberg S, Feldmann R, Schonauer K, Schulze Mönking H. Collaboration with drug
treatment by schizophrenic patients with and without psychoeducational training: results of a 1-year
follow-up. Acta Psychiatr Scand. 1998;97:213–9.
13. Feldmann R, Hornung WP, Prein B, Buchkremer G, Arolt V. Timing of psychoeducational
psychotherapeutic interventions in schizophrenic patients. Eur Arch Psychiatry Clin Neurosci. 2002;
252(3):115–9.
14. Naber D, Moritz S, Lambert M, Pajonk FG, Holzbach R, Mass R, et al. Improvement of schizophrenic
patients’ subjective well-being under atypical antipsychotic drugs. Schizophr Res. 2001;50:79–88.
15. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective
psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol. 1995;
10(suppl 3):133–8.
16. Watanabe M, Matsumura H. Reliability and validity of subjective well-being under neuroleptic drug
treatment short form, Japanese version (SWNS-J). Jpn J Clin Psychopharmacol. 2003;6:905–12.
17. Hogan TTP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics:
reliability and discriminative ability. Psychol Med. 1983;13:177–83.
18. Miyata R, Fujii Y, Inagaki A. Medical treatment and quality of life of the schizophrenic patients (Part 1).
A study of the stance for medicine by the questionnaire (Drug Attitude Inventory, Japanese version).
Psychiat Neurol Jap. 1996;98:1045–6.
19. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Schizophr Bull. 1987;13:261–76.
20. Kay SR, Opler LA, Fiszbein A (Translated from English by Yamada H, Masui K, Kikumoto K). Positive
and Negative Syndrome Scale (PANSS) Rating Manual. Tokyo: Seiwa Shoten Publishers; 1991.
21. Lambert M, Schimmelmann BG, Karow A, Naber D. Subjective well-being and initial dysphoric
reaction under antipsychotic drugs – concepts, measurement and clinical relevance. Pharmacopsychiatry.
2003;36 Suppl 3:S181–90.
10
Table 1. Topics of the psychoeducation program sessions
Session
1. Schizophrenia
Topics
Stress-vulnerability model, positive symptoms, negative
symptoms, cognitive impairment, course of schizophrenia,
prevention of recurrence
2. Drugs
Types and actions of drugs, checking each person’s drug booklet,
side effects
3. Stress coping
What is stress? Signs of stress, creating stress coping worksheets
4. Social resources
Participants were surveyed in advance about which topics among
residence, work, home help services, facility commuting services,
pension, disability certificate, and other topics they were most
interested in to determine the main topics of discussion.
11
Table 2. Comparison of SWNS-J score, DAI-10 score, and CPZE dose before and after the intervention
Before the program
After the program
p value*
Mean (SD)
Mean (SD)
13.5 (4.2)
15.4 (4.5)
<0.001
16.5 (4.1)
<0.001
SWNS-J
Mental Functioning
Self-Control
14.5 (4.2)
Emotional Regulation
14.2 (3.7)
15.2 (3.9)
0.013
Physical Functioning
14.5 (3.9)
15.5 (4.0)
0.002
Social Integration
13.8 (4.1)
15.8 (4.8)
<0.001
Total Score
71.4 (16.7)
78.0 (17.7)
<0.001
2.1 (4.1)
2.8 (4.2)
0.002
536.4 (356.3)
540.1 (356.1)
0.924
DAI-10
CPZE
*: paired t-test
SWNS-J: Subjective Well-being under Neuroleptic drug treatment Short form, Japanese version
DAI-10: Drug Attitude Inventory-10
CPZE: Chlorpromazine equivalent
12
Table 3. Factors associated with subjective well-being (SWNS-J) after the psychoeducation program:
Multiple regression analysis
Standardized
coefficient
t value
p value
VIF
0.530
7.006
<0.001
1.009
-0.161
-2.115
0.037
1.017
0.151
1.996
0.048
Beta
SWNS-J score before program
PANSS scale of negative symptoms
DAI-10 after program
1.012
Adjusted R = 0.341
13
...
論文の公開元へ
